NCT00229619View on ClinicalTrials.gov

Rituximab to Treat Moderate Aplastic Anemia, Pure Red Cell Aplasia, or Diamond Blackfan Anemia

PHASE2CompletedINTERVENTIONAL
Enrollment

11

Participants

Timeline

Start Date

September 30, 2005

Primary Completion Date

June 30, 2010

Study Completion Date

June 30, 2010

Conditions
Anemia, AplasticRed-Cell Aplasia, PureAnemia, Diamond-Blackfan
Interventions
DRUG

Rituximab

Rituximab (Rituxan) 375mg/m2 intravenous infusion. The infusion will be once every week for a total of 4 doses.

Trial Locations (1)

20892

National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda

All Listed Sponsors
lead

National Heart, Lung, and Blood Institute (NHLBI)

NIH

NCT00229619 - Rituximab to Treat Moderate Aplastic Anemia, Pure Red Cell Aplasia, or Diamond Blackfan Anemia | Biotech Hunter | Biotech Hunter